title: BlyS: a potential hallmark of multiple myeloma.
abstract: Multiple myeloma (MM) is a plasma cell dyscrasia characterized by bone lesions and production of a paraprotein. B-lymphocyte stimulator (BLyS) and its receptor (BAFFR) were highly expressed on peripheral blood and bone marrow B cells in MM patients as compared to those with monoclonal gammopathy of unknown significance (MGUS) and healthy donors. Serum BLyS levels in MM patients were significantly higher than those in MGUS patients and healthy controls. BLyS expression was increased in bone marrow specimens from MM patients as ascertained by immunofluorescence. Furthermore, BLyS, together with IL-2 and IL-6, significantly promoted MM cell proliferation and BLyS receptor expression compared with that in the control group. Treatment with bortezomib, a therapeutic proteasome inhibitor induced apoptosis and repressed the proliferation of RPMI8226 and U266 cells through inhibition of NF-κB p65 and IκBα. These findings suggest that BLyS is involved in the immunopathogenesis of MM and may prove to be a hallmark of MM.
authors.affiliation: Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, 227 South Chongqing Road, Shanghai 200025, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Liu
authors.initials: L
authors.lastname: Qian
authors.forename: Xiangliang
authors.initials: X
authors.lastname: Yuan
authors.forename: Chaoying
authors.initials: C
authors.lastname: Hu
authors.forename: Liansheng
authors.initials: L
authors.lastname: Wang
authors.forename: Qiuyu
authors.initials: Q
authors.lastname: Huang
authors.forename: Ping
authors.initials: P
authors.lastname: Miao
authors.forename: Qiwen
authors.initials: Q
authors.lastname: Yu
authors.forename: Yanhui
authors.initials: Y
authors.lastname: Ma
authors.forename: Jiying
authors.initials: J
authors.lastname: Zhang
authors.forename: Xuehua
authors.initials: X
authors.lastname: Chen
authors.forename: Bingya
authors.initials: B
authors.lastname: Liu
authors.forename: Lisong
authors.initials: L
authors.lastname: Shen
authors.forename: Dongqing
authors.initials: D
authors.lastname: Zhang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis / Q000187:drug effects; D053264:B-Cell Activating Factor / Q000096:biosynthesis*; D053265:B-Cell Activation Factor Receptor / Q000096:biosynthesis*; D001402:B-Lymphocytes / Q000378:metabolism; D001853:Bone Marrow / Q000378:metabolism; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000503:physiopathology*; D011719:Pyrazines / Q000627:therapeutic use
chemical_list: D053264:B-Cell Activating Factor; D053265:B-Cell Activation Factor Receptor; D001897:Boronic Acids; D011719:Pyrazines; C435926:TNFRSF13C protein, human; D000069286:Bortezomib